entertainment -WSS

entertainment

author：fashion 2025-09-02 11:46:24 - browse：18924

Closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. — A brain affected by Alzheimer's disease, at the Museum of Neuroanatomy at the University at Buffalo. David Duprey/AP

Investigators on Wednesday released the first detailed case report about a patient who died after receiving lecanemab, providing a new glimpse into safety concerns surrounding the closely watched experimental Alzheimer’s drug.

An unpublished version of the report was previously written about by Science in November, one of three deaths from the lecanemab trials revealed by Science and STAT. But the published version, in the New England Journal of Medicine, will allow doctors to evaluate the case as they consider whether and how to use a treatment that could be approved by the FDA as soon as this week.

This “will have greater impact on clinicians because it is peer-reviewed and published in the New England Journal,” said Lon Schneider, an Alzheimer’s expert at University of Southern California, who was not affiliated with the work.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Colonoscopy at 40? Study finds a possible benefit

WSS

In areas with more Black doctors, Black people live longer

Cloning humans is technically possible. It's curious no one has tried

Do masks work? RCTs can't tell us

Why are elite athletes different? Take a look at their microbes

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Doctors' information doesn't help them choose wisely when sick

hotspot

entertainment

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Industry veterans launch new biotech VC with $310M

BioMarin wins approval for gene therapy to treat hemophilia A

Do masks work? RCTs can't tell us

Cancer drug shortages should be causing more outrage

The battle over the Brookhaven Landfill on Long Island

Activists slam private health insurers over coverage restrictions

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Bright Health sells Medicare Advantage business to Molina

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

leisure time

'Revelatory' study finds a smoking impact that remains after quitting

'Revelatory' study finds a smoking impact that remains after quitting

Do masks work? RCTs can't tell us

KalVista pill reduced swelling 'attacks' caused by genetic disease

Medicare Advantage proposed rates disappoint insurers

Gilead might be held responsible for not developing a drug

hotspot

entertainment

leisure time

hotspot